ABP-671 is intended for the treatment of chronic gout. Credit: Orawan Pattarawimonchai / Shutterstock.

Chinese biotechnology company Atom Bioscience has dosed the first patient in a Phase IIb/III clinical trial of ABP-671 to treat chronic gout, one of the most common types of inflammatory arthritis.

The double-blind, multi-centre, randomised study intends to enrol 580 patients from the US and other nations.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The first part of the study will evaluate the efficacy and safety of the URAT1 inhibitor ABP-671 at different doses and regimens, while the second part will be a confirmatory study for dosing regimens selected from the first part.

Results from Part I are due to be published in the fourth quarter of next year.

According to many national gout treatment guidelines, maintaining serum uric acid (sUA) levels of 5mg/dL to 4mg/dL in gout patients is recommended.

In two Phase II studies of ABP-671, the patients dosed were given 1mg to 12mg of the formulation once a day.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These two studies showed that by dosing once daily, the efficacy of ABP-671 can be maintained for up to 24 hours.

Atom Bioscience CEO, chairman and founder Dr William Dongfang Shi said: “In terms of safety, ABP-671 is well-tolerated.

“Its adverse events were mostly Grade I (mild and generally not bothersome) and the incidence is comparable to that of the placebo group. No severe adverse events have occurred with ABP-671 at the dose tested.

“A Human Mass Balance study, which evaluates how drugs are absorbed, metabolised and excreted, showed that ABP-671 is mostly excreted in its original form and does not produce any of similar metabolites seen with benzbromarone (a currently marketed drug for gout treatment), which causes severe liver toxicity.”

Earlier this year, Atom Bioscience reported positive data from a Phase II study of ABP-671 for treating chronic gout.

Among patients given 1mg of ABP-671 once a day, 86% reached serum uric acid (sUA) levels of less than 6mg/dL.